Zydus Lifesciences Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is FEBUXOSTAT API, with a corresponding US DMF Number 26071.
Remarkably, this DMF maintains an Active status since its submission on May 31, 2012, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 11, 2013, and payment made on December 18, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II